KMT2D is an inclusion criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

KMT2D is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 1 is open and 2 are closed. Of the trials that contain KMT2D status and malignant solid tumor as inclusion criteria, 3 are phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2D status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KMT2D status and bladder carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain KMT2D status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2D status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

KMT2D is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain KMT2D status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KMT2D is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].